The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase disrupter of telomeric silencing 1-like (DOT1L). In this phase 1 study, pinometostat was evaluated for safety and efficacy in adult patients with advanced acute leukemias, particularly those involvi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Stein, Eytan M., Garcia-Manero, Guillermo, Rizzieri, David A., Tibes, Raoul, Berdeja, Jesus G., Savona, Michael R., Jongen-Lavrenic, Mojca, Altman, Jessica K., Thomson, Blythe, Blakemore, Stephen J., Daigle, Scott R., Waters, Nigel J., Suttle, A. Benjamin, Clawson, Alicia, Pollock, Roy, Krivtsov, Andrei, Armstrong, Scott A., DiMartino, Jorge, Hedrick, Eric, Löwenberg, Bob, Tallman, Martin S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2018
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6265654/
https://ncbi.nlm.nih.gov/pubmed/29724899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-12-818948
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge